Alzamend Neuro Inc (ALZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 04/30
| 10-2024 | 07-2024 | 04-2024 | 01-2024 | 10-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 4,093 | 1,194 | 376 | 283 | 200 |
| TOTAL | $4,767 | $1,416 | $455 | $594 | $782 |
| Non-Current Assets | |||||
| PPE Net | 241 | 254 | 176 | 189 | 202 |
| TOTAL | $241 | $254 | $176 | $189 | $202 |
| Total Assets | $5,008 | $1,670 | $632 | $783 | $984 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,255 | 2,882 | 2,925 | 3,827 | 3,666 |
| TOTAL | $1,255 | $2,882 | $3,226 | $3,827 | $3,666 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 0 | 1,220 | 0 |
| TOTAL | $N/A | $N/A | $N/A | $1,220 | $N/A |
| Total Liabilities | $1,255 | $2,882 | $3,226 | $5,047 | $3,666 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 604 | 432 | 93 | 76 | 79 |
| Common Shares | 1 | 0 | 0 | 1 | 1 |
| Retained earnings | -56,410 | -54,995 | -54,020 | -53,169 | -50,507 |
| Other shareholders' equity | 0 | 0 | 0 | -70 | -14,876 |
| TOTAL | $3,753 | $-1,212 | $-2,594 | $-4,264 | $-2,683 |
| Total Liabilities And Equity | $5,008 | $1,670 | $632 | $783 | $984 |